Pyxis Oncology Stock Analysis

Pyxis Stock Analysis Notes

About 25.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.69. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pyxis Oncology has Price/Earnings To Growth (PEG) ratio of 0.01. The entity recorded a loss per share of 1.06. The firm had not issued any dividends in recent years. Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Pyxis Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 67 people. To find out more about Pyxis Oncology contact MBA MD at 617 221 9059 or learn more at https://www.pyxisoncology.com.

Pyxis Oncology Investment Alerts

Pyxis Oncology Upcoming and Recent Events

Pyxis Largest EPS Surprises

View All Earnings Estimates

Pyxis Stock Institutional Investors

Note, although Pyxis Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Pyxis Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 105.85 M.

Pyxis Profitablity

Management Efficiency

Pyxis Oncology has return on total asset (ROA) of (0.2106) % which means that it has lost $0.2106 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3934) %, meaning that it created substantial loss on money invested by shareholders. Pyxis Oncology's management efficiency ratios could be used to measure how well Pyxis Oncology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.52 in 2024. Return On Capital Employed is likely to drop to -0.58 in 2024. At this time, Pyxis Oncology's Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 16.4 M in 2024, whereas Net Tangible Assets are likely to drop slightly above 111 M in 2024.

Technical Drivers

As of the 11th of December 2024, Pyxis Oncology holds the Coefficient Of Variation of (878.47), variance of 52.12, and Risk Adjusted Performance of (0.07). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pyxis Oncology, as well as the relationship between them. Please check Pyxis Oncology risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and kurtosis to decide if Pyxis Oncology is priced some-what accurately, providing market reflects its current price of 1.68 per share. Please also confirm Pyxis Oncology jensen alpha, which is currently at (0.79) to check out the company can sustain itself at a future point.

Pyxis Oncology Price Movement Analysis

Pyxis Oncology Insider Trading Activities

Pyxis Oncology Outstanding Bonds

Pyxis Oncology Predictive Daily Indicators

Pyxis Oncology Forecast Models

Pyxis Oncology's time-series forecasting models are one of many Pyxis Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pyxis Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Pyxis Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pyxis shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pyxis Oncology. By using and applying Pyxis Stock analysis, traders can create a robust methodology for identifying Pyxis entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pyxis analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pyxis analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Pyxis Oncology stock analysis indicators help investors evaluate how Pyxis Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Pyxis Oncology shares will generate the highest return on investment. By understating and applying Pyxis Oncology stock analysis, traders can identify Pyxis Oncology position entry and exit signals to maximize returns.

When running Pyxis Oncology's price analysis, check to measure Pyxis Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pyxis Oncology is operating at the current time. Most of Pyxis Oncology's value examination focuses on studying past and present price action to predict the probability of Pyxis Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pyxis Oncology's price. Additionally, you may evaluate how the addition of Pyxis Oncology to your portfolios can decrease your overall portfolio volatility.